Looks like India might be becoming downright hostile to Western drug company IP positions in that country. Today, India revoked two more patents held by Allergan for a couple of eye drugs -- Ganfort and Combigen. See Economic Times.
So now you can add that on top of patents strcuk down in the past couple years for Bayer's Nexavar, Pfizer's Sutent, GSK's Tykerb, Novartis' Gleevec, and Roche's Pegasys and Herceptin. Add in the two Allergan drugs and we're talking serious revocation.
Wow, it's getting to be tough if you want to market Western drugs in India. If it keeps going this direction, maybe we won't have any Western drugs in India. Sounds like the British bookmakers ought to start issuing odds on next drugs to be cited for "lack of innovation" in India.
Posted by Bruce Lehr Aug 12th 2013.